30: An integrated genetic-protein analysis of the TNF-family pathway predicts for GVHD  by Levine, J.E. et al.
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A MULTICENTER PROSPECTIVE RANDOMIZED PHASE II STUDY IN
PATIENTS WITH CORTICOSTEROID-REFRACTORY/DEPENDENT/INTOL-
ERANT CHRONIC CUTANEOUS GVHD GIVEN EITHER EXTRACORPO-
REAL PHOTOIMMUNE THERAPY WITH UVADEX IN CONJUNCTION
WITH CONVENTIONAL THERAPY OR CONVENTIONAL THERAPY ALONE
Greinix, H.T.1, Van Besien, K.2, Apperley, J.3, Bacigalupo, A.4,
Elmaagacli, A.5, Grigg, A.6, Kolb, H.-J.7, Bouzas, L.8, Michallet, M.9,
Reddy, V.S.10, Knobler, R.M.1, Wang, J.11, Williamson, P.11,
Flowers, M.E.D.12 1Medical University of Vienna, Vienna, Austria;
2University of Chicago, Chicago; 3Royal Hammersmith Hospital London,
London, United Kingdom; 4Universitaria San Martino, Genova, Italy;
5Universitaets-Klinikum Essen, Essen, Germany; 6Royal Melbourne
Hospital, Melbourne, Australia; 7Ludwig-Maximillians-Universitaet
Muenchen, Munich, Germany; 8INCa, Rio de Janeiro, Brazil; 9Hopital
Edouard Herriot, Lyon, France; 10University of Florida, Gainesville,
FL; 11Therakos Inc., Exton, PA; 12Fred Hutchinson Cancer Center and
University of Washington, Seattle, WA.
Chronic GVHD (cGVHD) is a major complication of allogeneic
hematopoietic stem cell transplantation (HSCT) and a leading
cause of non-relapse mortality. Extracorporeal photoimmune ther-
apy (ECP) has been used in retrospective and Phase II trials of
patients with cGVHD. The mechanism of action of ECP is elusive
but it appears to promote apoptosis and induce immune tolerance.
In this randomized, prospective study, we compared the safety and
efﬁcacy of ECP used in conjunction with conventional therapy
(calcineurin inhibitor 	 mycophenolate mofetil) and steroids to
conventional therapy alone in patients with steroid-refractory/
dependent/intolerant cutaneous cGVHD. In the ECP arm, pho-
topheresis was administered twice weekly for 12 weeks, then twice
monthly until Week 24; patients in the non-ECP arm could with-
draw from study after Week 12 if no beneﬁcial response was
observed or earlier if cGvHD worsened and enter a separate
extension study that included ECP. The primary efﬁcacy endpoint
was percent change from baseline in skin assessment score (Total
Skin Score; TSS) of 10 body regions graded from 0 to 5 (0 
normal, 1 discolored, 2  lichenoid, 3  thickened, 4  hide-
bound, 5  grades 3 or 4 with erythema; maximum score of 50) by
a trained blinded observer at week 12. All efﬁcacy analyses were
conducted on the modiﬁed intent-to-treat (MITT) patients who
had at least one treatment and one post-baseline TSS. Ninety-ﬁve
MITT patients (56 M, 39 F; median age  41 years) with steroid
refractory (n  12), intolerant (n  30) or dependent (n  57)
histologically-conﬁrmed cGVHD were randomized to receive
ECP and conventional therapy (n  48) or conventional therapy
alone (n  47). Study arms were balanced except for more GI
involvement in the non-ECP arm. Ninety-four percent in both
study arms had extensive cGVHD. 44 (92%) patients in the ECP
arm and 41 (87%) in the non-ECP arm completed the ﬁrst 12
weeks and those results are summarized in the table. ECP was
well-tolerated with a safety proﬁle consistent with previous studies.
Thus, ECP is effective in skin manifestations and steroid sparing in
steroid-refractory/dependent/intolerant chronic GVHD.
ECP
Non-
ECP
p
Value
Median Baseline TSS 9.4 9.2
Median % Improvement in TSS 14.5 10.4 0.510
Median % Improvement in pts
with TSS >-10 at baseline 21.9 12.1 0.418
% pts with >-50% Reduction in
Steroid Dose 29 14 0.089
% pts with >-50% Reduction in
Steroid Dose AND final
Steroid Dose < 10 mg/day 24 7 0.027
% pts with >-50% Reduction in
Steroid Dose AND >-25%
Reduction in TSS 10 0 0.040
% pts with CR and PR of Skin
by Investigator Assessment 40 10 0.0024
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RAPID EXPANSION OF ACUTE MYELOID LEUKEMIA-REACTIVE CYTO-
TOXIC T CELLS FROM CD8CD62L BLOOD LYMPHOCYTES OF HLA-
MATCHED HEALTHY DONORS IN VITRO
Distler, E.1, Woelfel, C.1, Pesth, S.1, Kaus, N.1, Wehler, T.C.1,
Meyer, R.G.1, Nonn, M.1, Hartwig, U.F.1, Huber, C.1, Woelfel, T.1,
Herr, W.1 1University of Mainz - Department of Medicine III, Mainz,
Germany.
Allogeneic cytotoxic T-lymphocyte (CTL) therapy in acute my-
eloid leukemia (AML) is hampered by the poor efﬁciency in grow-
ing leukemia-reactive CTLs from healthy donors in vitro. We
established an allogeneic mini-mixed lymphocyte-leukemia culture
(MLLC) approach by stimulating comparably small numbers (104/
well) of CD8 T cells isolated from peripheral blood of healthy
donors against primary AML blasts in 96-well plates. Prior to use,
CD8 T cells were immunomagnetically separated into a
CD62L(high) subset enriched for naive precursors and central
memory cells as well as a CD62L(low)/negative subset containing
effector memory cells. Mini-MLLCs were performed in seven
healthy donor-AML pairs that were matched for HLA class I
according to high-resolution sequence-based typing. Following 2
weekly re-stimulations with primary AML blasts, mini-MLLC
responder populations were tested using split-well IFN-gamma
ELISPOT assay. AML-reactive CD8 T-cell responders were
obtained from all 7 donor-AML pairs with the majority of reactive
cultures originally seeded with CD62L(high) cells. In 4 out of 7
pairs most MLLC responder populations recognized AML blasts,
but not Epstein-Barr virus transformed B-lymphoblastoid cell lines
of donor and patient origin. This leukemia reactivity was restricted
by various HLA class I alleles. Representative mini-MLLC re-
sponders demonstrated strong cytotoxicity against AML blasts in
51Chromium-release assay. Cross-reactivity testing identiﬁed an
HLA-A*0201-restricted CTL population that showed much stron-
ger recognition of AML blasts compared to their non-malignant
monocytic counterparts. This CTL did not recognize recipient-
derived primary ﬁbroblasts or other hematopoietic cells suggesting
a leukemia-associated rather than a minor histocompatibility anti-
gen as the target structure. Several MLLC-derived CTL popula-
tions expressed unique T cell receptor Vbeta chains consistent with
clonal derivation from AML-reactive precursors. Multiple CTL
responders reached a cell yield exceeding 108 by 6 to 10 weekly
re-stimulations with AML blasts. Our results suggest that in
healthy individuals most AML-reactive CD8 CTLs originate
from the CD62L(high) peripheral blood subpopulation contain-
ing naive precursor and central memory T cells. This mini-MLLC
approach should allow the expansion of AML-reactive CD8
CTLs from HLA-matched healthy donors to cell numbers sufﬁ-
cient for antigen identiﬁcation strategies or adoptive immunother-
apy trials.
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AN INTEGRATED GENETIC-PROTEIN ANALYSIS OF THE TNF-FAMILY
PATHWAY PREDICTS FOR GVHD
Levine, J.E.1, Kitko, C.1, Goyal, R.2, Ferrell, R.2, Braun, T.1,
Mullighan, C.3, Hanauer, D.1, Choi, S.1, Paczesny, S.1, Mineishi, S.1,
Cooke, K.P.1, Jones, D.1, Whitﬁeld, J.1, Yanik, G.1, Ferrara, J.L.M.1
1University of Michigan, Ann Arbor, MI; 2Children’s Hospital of Pitts-
burgh, Pittsburgh, PA; 3St. Jude Children’s Research Hospital, Mem-
phis, TN.
Although the major cause of morbidity and treatment-related
mortality (TRM) after allogeneic HSCT is GVHD, there is no
predictive laboratory test for GVHD. Because tumor necrosis
factor- (TNF) plays an important role in GVHD pathogenesis we
tested the hypothesis that elevations in TNF levels on day 7 would
predict the development of signiﬁcant GVHD and treatment-
related mortality (TRM). We measured soluble TNF receptor 1
(TNFR1) as a surrogate for TNF because TNF circulates as a
ligand-receptor complex. We studied samples obtained under in-
formed consent from 438 patients undergoing allogeneic HSCT
following myeloablative conditioning at the University of Michi-
gan between 2000 and 2005. The median age of the patients was
42y (range 0-65y). The distribution of donors by degree of HLA-
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match and type was: 5 or 6/6 HLA-matched related donors
(n267), 5 or 6/6 matched unrelated donors (n171). The median
day of onset of GVHD grade 2-4 for related donors was 30d and
for unrelated donors was 20d.
We expressed the day 7 value as a ratio to pre-transplant baseline.
The mean day 7 TNFR1 ratios strongly correlate with severity of
GVHD: 1.9 (GVHD 0-1, n269), 2.3 (GVHD 2, n83), and 2.9
(GVHD 3-4, n86), p0.001.
When treated as a continuous variable, day 7 TNFR1 ratios
strongly correlated with both the likelihood of GVHD 2-4
(p0.001) and 1yr TRM (p0.001). Patients with a day 7 TNFR1
ratio above 2.5 (approximately the mean ratio for patients with
GVHD 2-4), were much more likely to experience GVHD and die
within the ﬁrst year from TRM, independent of donor source
[Table 1].
Recipient DNA samples were available for 222 subjects who were
similar to the entire cohort with respect to age, donor type, degree
of match, conditioning regimen, TNFR1 ratios and incidence of
GVHD 2-4. Sixteen single nucleotide polymorphisms (SNPs)
known to have functional relevance for the TNF axis (TNF-,
TNFRSF1A (encoding TNFR1), and TNFRSF1B (encoding
TNFR2)) were analyzed. One SNP (TNFRSF1B 1690 T/C) was
found to have a statistically signiﬁcant association with the day 7
TNFR1 ratio (2.2 vs 1.8, p  0.04) and probability of GVHD 2-4,
after adjustment for the TNFR1 ratio (45% vs 22%; p  0.02). In
conclusion, we have observed a clinically important relationship
between genetic polymorphisms and post-transplant expression of
TNF pathway proteins. Improved understanding of this relation-
ship may allow for a risk-adjusted approach to GVHD prevention.
Table 1
TNFR1 ratio - All patients (n438) GVHD 2-4 1y TRM
TNFR1 ratio <2.5 (n328) 32% 17%
TNFR1 ratio >2.5 (n110) 58% 39%
p<0.001 p<0.001
TNFR1 ratio - related donors (n267)
TNFR1 ratio <2.5 (n210) 26% 11%
TNFR1 ratio >2.5 (n57) 50% 29%
p<0.001 p0.007
TNFR1 ratio - unrelated donors (n171)
TNFR1 ratio <2.5 (n118) 43% 28%
TNFR1 ratio >2.5 (n53) 65% 49%
p0.001 p0.01
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TUMOR-ACTIVATED HUMAN NK CELLS – POTENTIAL FOR “OFF-THE-
SHELF” IMMUNOTHERAPY
Lowdell, M.W.1, North, J.1, Bakhsh, I.1, Marden, C.1, Anderson, R.1,
Pittman, H.1, Mackinnon, S.1 1Department of Haematology, Royal Free
& UCL Medical School, London, United Kingdom.
Resting human NK cells can be primed to lyse NK–resistant
tumor cells by pre-incubation with lysates of the leukemic cell line
CTV-1. The primed NK cells demonstrate tumor-restricted lysis
in vitro. NK cells isolated from normal healthy donors and co-
incubated with irradiated CTV-1 lysates synthesized CD69 within
60 min with maximal expression achieved within 6 hr. The tumor-
activated NK cells (T-ANKs) lysed NK resistant RAJI and Daudi
cells in a 4-hour assay. The degree of lysis was equivalent to that of
matched lymphokine activated killer cells (LAK) after non-speciﬁc
activation with IL-2. CTV-1 cells are HLA-C type 2 homozygous
and express HLA-Bw4 alleles. They thus can ligate KIR2DL1
(CD158a) and KIR3DL1 (CD158e1) on NK cells. Co-cultures of
HLA-matched or mis-matched NK with CTV-1 showed there was
no signiﬁcant difference in the generation of T-ANK activity in
the presence or absence of KIR ligation. T-ANK cells from allo-
geneic donors were capable of lysis of primary AML cells of all
FAB types, primary CML blasts, the relatively NK-resistant breast
cancer cell line, MCF-7, and primary tumor cells isolated from
resected tissue from patients with breast cancer and ascities from
patients with ovarian cancer. T-ANK cells from ﬁve AML patients
in CR consistently induced signiﬁcantly greater lysis of autologous
AML blasts than the matched NK cells (p0.05). Allogeneic T-
ANK cells were compared with NK cells from the same donor with
respect to lysis of normal autologous and allogeneic PBMC. Nei-
ther NK nor T-ANK cells lysed autologous PBMC nor did they
lyse PBMC from HLA-C mismatched normal donors. To deter-
mine the likelihood of bone marrow suppression by T-ANK cells
we established hematopoietic colony forming assays with bone
marrow from 5 normal donors and added T-ANK from HLA-C
mismatched donors at increasing ratios. CFU-GM, BFU-E and
CFU-GEMM were not affected by co-incubation with HLA-mis-
matched T-ANK even at effector:target ratios of 20:1. Further-
more, pooled TaNK generated from multiple donors showed
equivalent in vitro activity to that of single donor products.We
believe that this demonstrates a two stage process for NK activa-
tion; priming and triggering, the ligands for which are distinct.
Tumor priming of NK primes cells capable of lysing a broad
spectrum of NK-resistant tumors irrespective of KIR ligation.
They are readily generated to clinical-grade and may represent an
“off-the-shelf” immunotherapy product.
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SINGLE VERSUS DOUBLE UMBILICAL CORD BLOOD TRANSPLANTA-
TION (UCBT): HIGHER RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE
(GVHD) BUT LOWER TRANSPLANT RELATED MORTALITY (TRM) IN
RECIPIENTS OF DOUBLE UCBT
MacMillan, M.L.1, Brunstein, C.1, DeFor, T.E.1, Blazar, B.R.1,
Weisdorf, D.J.1, Wagner, J.E.1 1University of Minnesota, Minneapolis,
MN.
Transplantation of 2 partially HLA matched UCB units has been
shown to be a safe and effective means to overcome the cell-dose
barrier in adolescents and adults. In addition, preliminary data
suggest that double UCBT is associated with a greater graft-
versus-leukemia effect (Blood 2005:106:93a). To date, there has
been no comparative analysis on the risk of acute GVHD in this
population of patients. Therefore, we compared rates of acute
GVHD in recipients of single (n210) versus double (n169)
UCBT. Double UCB recipients were more likely to be older,
transplanted in recent years, treated with a non myeloablative
therapy, received mycophenolate mofetil as GVHD prophylaxis,
and less likely to receive antithymocyte globulin (ATG) as part of
the conditioning. Incidences of grades II-IV and III-IV acute
GVHD were higher in recipients of double than single UCBT
recipients (60% vs 33%, p.01) and (21% vs 11%, p.01), respec-
tively. Adjusting for differences between groups, two factors were
associated with the development of grade II-IV acute GVHD in
Cox regression: use of 2 UCB units (RR 2.0 vs 1.0 [95% CI,
1.3-3.2, p.01]) and absence of ATG in the preparative regimen (RR
1.0 vs 0.5 [95% CI, 0.3-0.8, p.01]). Other factors that were tested
in the model but not determined to be signiﬁcantly associated with
acute GVHD were recipient age, gender, weight, diagnosis, time
from diagnosis to UCBT, HLA disparity, total and CD3 cell dose,
CMV serostatus, conditioning regimen, and GVHD prophylaxis.
Despite increased risk of acute GVHD, TRM 1 year was signiﬁ-
cantly lower in recipients of double UCBT (17%, 95% CI, 5-29%)
as compared to recipients of a single UCBT (47%, 95% CI,
26-68%; p .02) among those that developed grade III-IV acute
GVHD. Survival at 1 year among those with grade III-IV acute
GVHD was signiﬁcantly higher after double UCBT (67%, 95%
CI, 51-83%) than after single UCBT (41%, 95% CI 21-61%;
p.04). In conclusion, risk of acute GVHD is signiﬁcantly higher
in recipients of two partially HLA matched UCB units, yet it does
not appear to adversely effect TRM or survival. ATG in the
preparative therapy, however, does not appear to reduce TRM
despite its favorable association with reduced GVHD. Impact of
GVHD on immune recovery and infection risk in recipients of
single and double UCBT is under investigation.
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